Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,087 shares of the biopharmaceutical company’s stock after purchasing an additional 3,874 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.07% of Halozyme Therapeutics worth $4,117,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares during the last quarter. Snyder Capital Management L P boosted its holdings in Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock valued at $199,294,000 after purchasing an additional 105,086 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock valued at $92,446,000 after purchasing an additional 47,795 shares during the last quarter. Northern Trust Corp boosted its holdings in Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock valued at $87,386,000 after purchasing an additional 145,617 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Halozyme Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock valued at $85,254,000 after purchasing an additional 9,780 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now directly owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. This represents a 1.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,697 shares of company stock valued at $1,276,552 in the last ninety days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $53.29 on Tuesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The firm’s 50 day moving average price is $60.54 and its 200 day moving average price is $55.95. The company has a market cap of $6.57 billion, a P/E ratio of 15.54, a PEG ratio of 0.42 and a beta of 1.26. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period in the prior year, the firm earned $0.79 EPS. The firm’s revenue for the quarter was up 35.2% on a year-over-year basis. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on HALO shares. Benchmark lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. Leerink Partners lowered shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a report on Tuesday, May 13th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.